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Abstract
Objectives: To assess the efficacy and safety of a methylphenidate hydrochloride extended-release capsule (MPH-MLR)
formulation in treating attention-deficit/hyperactivity disorder (ADHD) in preschool children.
Methods: Children aged 4 to <6 years with qualifying ADHD Rating Scale Fourth Edition (ADHD-RS-IV) Preschool Version
scores (‡90th percentile for age/gender) participated in four behavior management training (BMT) sessions or immediately
entered (based on investigator assessment of symptom severity or previous participation) into a 6-week, open-label, flexible
MPH-MLR dose optimization phase. After BMT, children with <30% improvement in ADHD-RS-IV score and ‡3 score on
the Clinical Global Impression—Improvement (CGI-I) scale also entered the open-label period. All children began the open-
label period with MPH-MLR 10 mg once daily; weekly adjustments permitted once-daily maximum of up to 40 mg. Children
with ‡30% improvement in ADHD-RS-IV total score and a CGI-I score of 1–2 at open-label completion were randomized to
their optimized dose of MPH-MLR or placebo for 2 weeks (double blind [DB]). Safety measures included adverse events
(AEs), vital signs, and electrocardiograms.
Results: Open-label enrollment was 119 children. Mean (SD) ADHD-RS-IV total scores at open-label start and open-label
end was 40.8 (10.4) and 19.5 (11.1), respectively. Ninety children were enrolled in the DB phase. Mean (SD) ADHD-RS-IV
total scores for the MPH-MLR and placebo group were similar at DB beginning and was 25.8 (14.6) and 34.9 (14.1),
respectively, at DB end. Mean change from baseline in ADHD-RS-IV total score during DB was significantly greater in
children randomized to placebo compared with MPH-MLR; least squares mean change difference from baseline was -11.2,
p = 0.002. During open-label dosing, the most common AEs (‡10%) were decreased appetite, decreased weight, insomnia,
hypertension, emotional disorder, and affect lability.
Conclusion: Results demonstrate MPH-MLR efficacy in preschool children and a safety profile consistent with known AEs
of methylphenidate when used for ADHD.
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Evidence-based management of attention-deficit/hyperactivitydisorder (ADHD) in children of preschool age is an emerging
priority for clinicians and regulatory agencies (Center for Drug
Evaluation and Research 2016). The reported prevalence of ADHD
in preschool children has been estimated to range from 0.5%
to 12.2% (Suvarna and Kamath 2009; Baker et al. 2010; Brault
and Lacourse 2012; Wichstrom et al. 2012; Nomura et al. 2014;
Ezpeleta and Granero 2015; Danielson et al. 2017). In children
<6 years of age, ADHD is the most common psychiatric reason for
referral to a specialized child and adolescent psychiatry clinic
(Gadow et al. 2001; Wilens et al. 2002; Lumu et al. 2015), and is
associated with substantial burden for children and their families.
More than 40% of preschoolers who meet ADHD diagnostic cri-
teria are suspended from school or daycare, compared with only
0.5% of children without ADHD; *16% are expelled (Egger and
Angold 2006).
Well-investigated treatment options for preschoolers with
ADHD are limited. Dextroamphetamine is the only medication
approved by the U.S. Food and Drug Administration (FDA) to treat
ADHD in children in this age group; however, randomized con-
trolled trials supporting its efficacy and safety are lacking (Wol-
raich et al. 2011). In its 2011 guidance, the American Academy of
Pediatrics (AAP) Clinical Practice Guidelines for the Diagnosis,
Evaluation and Treatment of Attention-Deficit/Hyperactivity Dis-
order in Children and Adolescents recommended behavior therapy
as first-line treatment in 4- to 5-year-olds, and treatment with
methylphenidate (MPH) if ADHD symptoms do not improve sig-
nificantly with behavior therapy (Wolraich et al. 2011). These
recommendations were advanced despite the lack of an FDA-
approved MPH product, based on placebo-controlled data dem-
onstrating the efficacy and safety of immediate-release (IR) MPH
in children aged 4 to 5 years in the National Institute of Mental
Health-funded Preschool ADHD Treatment Study (PATS)
(Greenhill et al. 2006; Kollins et al. 2006; Abikoff et al. 2007).
Many child psychiatrists do not follow the AAP guidelines.
A survey that included 339 board-certified child and adolescent
psychiatrists found that only 7.4% of practitioners first used be-
havioral therapy in preschool children (Chung et al. 2016). Physi-
cians cited physical safety and educational concerns as the most
important reasons to begin immediate pharmacological treatment.
Therefore, it is important for clinicians to have data to support
treatment choices.
Many children of preschool age are treated with extended du-
ration stimulant formulations, despite the fact that these medica-
tions are not FDA approved for 4- and 5-year-olds. Prescription
data from Oregon Medicaid in 2012, after release of the AAP
guidelines for children <6 years of age with ADHD, showed that
91.4% of prescriptions for ADHD treatment in children <6 years of
age were off-label (Panther et al. 2017). Of the MPH prescriptions
in this population, 457 were for IR MPH and 459 were for
extended-release (ER) MPH. Yet, class labeling for all MPH for-
mulations begins at age 6. Consequently, randomized controlled
trials for ER MPH in preschoolers are needed to provide essential
efficacy and safety data for this vulnerable population, and are now
required by FDA.
Methylphenidate hydrochloride ER capsules (Aptensio XR;
Rhodes Pharmaceuticals L.P., Coventry, RI), formulated as multiple-
layer release (MLR) beads in hard gelatin capsules (methylphenidate
hydrochloride extended-release capsules [MPH-MLR]), received
FDA approval in April 2015 for treatment of ADHD in children
‡6 years of age to manage ADHD symptomatology (Aptensio
XR [methylphenidate extended release] 2017); approval was
based on efficacy persisting from Hour 1 postdose to Hour 12
postdose (Wigal et al. 2014, 2015). After oral dosing, MPH-MLR
exhibits a biphasic plasma profile by achieving a first peak con-
centration in a similar manner to IR MPH, and a second peak
concentration at *6 to 8 hours (Adjei et al. 2014).
In response to the FDA mandate for additional studies of MPH
in preschool-age children, and consistent with the AAP guidelines
for treatment of ADHD in this population, this study was under-
taken to evaluate the safety and efficacy of MPH-MLR in preschool
children who did not benefit from *4 weeks of behavior man-
agement training (BMT; NCT02683265).
Methods
Study design
The study was a randomized, double-blind (DB), flexible-dose,
placebo-controlled, parallel-group design conducted in six se-
quential phases (Fig. 1) at 11 U.S. sites. Phase 1 was screen-
ing/washout and lasted up to 28 days. A semistructured interview,
the Kiddie Schedule for Affective Disorders and Schizophrenia for
School-Age Children—Present and Lifetime version (K-SADS-
PL) (Birmaher et al. 2009) was administered by trained clinicians to
confirm the diagnosis of ADHD and identify comorbid psychiatric
conditions. If the child had previously received stimulant medica-
tion, a minimum of 3-day washout period was required before the
child entered Phase 2.
BMT was required (four visits ‡90-minute duration) during a
2- to 4-week period; the primary caregivers were the primary at-
tendees for these sessions. The content for this training was adapted
from empirically validated interventions (Cunningham et al. 1995;
Barkley 1997; Wells et al. 2000). Waivers for BMT were available
if the child and primary caregiver had, in the previous 12 months,
participated in a documented course of nonpharmacological treat-
ment with minimal benefit, or the child exhibited ADHD symptoms
and impairment that warranted immediate pharmacological treat-
ment, as assessed by the investigator. Evidence for a waiver was
reviewed and approved by the study’s principal investigator and
medical monitor.
Phase 3 began with two baseline visits after completion of BMT.
During the first baseline visit, study eligibility was confirmed and
the ADHD Rating Scale Fourth Edition (ADHD-RS-IV) Preschool
Version (McGoey et al. 2007), the Clinical Global Impression—
Severity (CGI-S), and Clinical Global Impression—Improvement
(CGI-I) (Guy 1976) assessments were administered. Continuation to
the open-label Phase 4 required that children had a <30% improve-
ment from screening in the ADHD-RS-IV Preschool Version total
score (Birmaher et al. 2009) and a CGI-I score of ‡3 (minimally
improved or less) after BMT. If continued eligibility was confirmed,
medical evaluation, including vital signs and collection of blood for
laboratory assessment, was completed and study drug was dispensed.
During the 6-week, open-label Phase 4, treatment was initiated
for each child with a once-daily dose of MPH-MLR 10 mg ad-
ministered in the morning. At weekly visits, a child’s current dose
was maintained, increased, or decreased based on clinician as-
sessment of response and reported adverse events (AEs), until an
optimized dose or the protocol-specified maximum dose of 40 mg
was reached. When compared with scores recorded just before
Phase 4 entry, the optimal dose was defined as the dose associated
with a reduction of ADHD symptoms ‡30%, a CGI-I score of
‘‘much improved’’ or ‘‘very much improved,’’ and tolerable AEs.
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Children who achieved an optimized dose during Phase 4 were
eligible to participate in the 2-week, parallel-arm, DB Phase 5. Chil-
dren were randomized in a 1:1 ratio through a computer-generated
randomization schedule to either continue their optimized dose or
receive matching placebo. Children who after 1 week of DB dosing
had a ‡50% worsening of symptoms from the start of Phase 5 (based
on their ADHD-RS-IV total score) and a CGI-I of ‘‘much worse’’ or
‘‘very much worse’’ compared with the start of Phase 5 were eligible
to discontinue the DB phase and enter the open-label extension study.
At the end of the 2-week, DB period, ADHD-RS-IV Preschool
Version, CGI-S, CGI-I, physical examination, and electrocardio-
gram were repeated and AEs were recorded. Children for whom
these procedures were not completed were ineligible to continue
with the open-label extension study. Children who completed all of
Phase 5 and continued to meet all inclusion/exclusion criteria were
eligible to enter the 12-month, open-label extension safety study.
A follow-up call (Phase 6), during which ongoing AEs and con-
comitant medications were recorded, occurred *2 weeks after
discontinuation of DB treatment, unless the child was eligible and
enrolled in the open-label extension study.
This study was conducted in accordance with the ethical principles
that originate from the Declaration of Helsinki and consistent with the
International Conference on Harmonisation of Technical Require-
ments for Registration for Pharmaceuticals for Human Use guidelines
on good clinical practice and regulatory requirements, as applicable.
Participants
Male and female children aged 4 years and 0 months to 5 years
and 8 months were enrolled if they met the Diagnostic and Statis-
tical Manual of Mental Disorders, Fifth Edition, criteria for ADHD
with symptoms present for ‡6 months. Diagnosis was confirmed
with the K-SADS-PL. Children must have also had age- and sex-
adjusted ratings of ‡90th percentile total score on the ADHD-RS-
IV Preschool Version (rated over the previous 6 months), a Child
Global Assessment Scale (Shaffer et al. 1983) score of <65, a CGI-
S score ‡4, and an IQ ‡80, as assessed using the Kaufman Brief
Intelligence Test, Second Edition (Kaufman and Kaufman 2004).
Blood pressure (BP; systolic and diastolic) was required to be <95th
percentile for age and gender.
Children were excluded from participation if they showed a lack
of response to a trial of adequate dose and duration of MPH and
intolerance to previous MPH treatment; were receiving psycho-
tropic medication other than clonidine, guanfacine, atomoxetine,
FIG. 1. Study design. ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale Fourth Edition; AE,
adverse event; ANOVA, analysis of variance; CGI-I, Clinical Global Impression—Improvement; CGI-S, Clinical Global Impression—
Severity; DBC-15, children in the double-blind compliant population who had 15 – 3 days of participation in the double-blind phase
of the study; ITT-E, intention-to-treat—efficacy evaluable; KBIT, Kaufman Brief Intelligence Test; MPH-MLR, methylphenidate
hydrochloride extended-release capsules; PT, parental behavior training.
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and/or stimulants; had taken an investigational drug in the 30 days
before screening; or had used monoamine oxidase inhibitors within
14 days before screening.
Treatment
Doses of MPH-MLR permitted by protocol in Phases 4 and 5 of
this study were 10, 15, 20, 30, and 40 mg. Nonsedating antihista-
mines, acetaminophen, ibuprofen, antibiotics for treatment of a
minor illness, and vitamins were permitted during the study.
Children participating in psychotherapy before study initiation
were permitted to continue; however, initiation of psychotherapy
was not permitted during the study.
Endpoints
The primary efficacy endpoint was change in ADHD-RS-IV
total score during the DB phase. Secondary endpoints were change
in ADHD-RS-IV hyperactivity/impulsivity and inattention sub-
scales, change in CGI-S and CGI-I ratings, and change in the
Conners Early Childhood Behavior—Parent Short Response scale
(Conners 2009).
Safety evaluations included the profile and frequency of AEs,
clinical laboratory evaluations (hematology, serum chemistry, and
urinalysis), physical examinations (including height and body
weight), vital signs (temperature, BP, and heart rate), electrocar-
diogram, the Columbia Suicide Severity Rating Scale, and the
Children’s Sleep Habits Questionnaire (CSHQ) (Owens et al. 2000).
Specific guidance was provided for the measurement of BP: (1) BP
had to be recorded after 5 minutes of rest in a sitting position; (2)
manual or automated BP systems were permitted; (3) interpretation
of on-study BP used the Department of Health and Human Services
pocket guide (National High Blood Pressure Education Program
Working Group on High Blood Pressure in Children and Adolescents
2007); and (4) individual instances of BP measurement that met the
criteria for hypertension were to be recorded as an AE.
Analysis
Several populations were defined for purposes of data analysis: (1)
safety population, including all children receiving at least one dose or
partial dose of study treatment; (2) intention-to-treat (ITT) popula-
tion, including all children randomized to treatment in the DB Phase
5; and (3) ITT—efficacy evaluable (ITT-E) population, including all
children in the ITT population who completed ADHD-RS-IV as-
sessments at the end of the open-label Phase 4 (DB phase baseline)
and had at least one postbaseline ADHD-RS-IV assessment.
Post hoc analyses examined data in the population of DB
compliant (DBC) subjects—that is, children in the ITT-E popula-
tion with nonmissing ADHD-RS-IV total scores for Visits 13, 14,
and 15. The DBC-15 population included those subjects in the DBC
with 15 – 3 days of participation in Phase 5. These analyses were
intended to explore the possible effects of protocol-specified per-
mission for children to withdraw from the DB phase before com-
pleting 2 weeks on DB treatment.
Sample size determination was based on a two-sample t-test,
assuming a mean increase from baseline in the ADHD-RS-IV total
score of 1.5 in the MPH-MLR arm and 10 in the placebo arm, and
assuming a standard deviation of 11 for the mean change in either
group. Enrollment of 74 children (37 in each treatment group)
would result in 90% power to detect a treatment difference of -8.5
points on the ADHD-RS-IV total score at a two-sided significance
level of 0.05.
Analysis of the primary efficacy endpoint was through a two-
way analysis of variance (ANOVA), using each child’s change in
ADHD-RS-IV total score during the DB phase. Statistical tests
were two-sided and values of p £ 0.05 were considered statistically
significant. The ANOVA model included two fixed factors, treat-
ment group and investigative site; the model also included a term
for treatment by site interaction. The dependent variable in the
ANOVA model was the change in ADHD-RS-IV total score from
baseline to the last postbaseline ADHD-RS-IV total score available
for each subject. Sites with fewer than 10 subjects in the analysis
population were combined into a single site for purposes of data
analysis. There was no imputation of missing values of ADHD-RS-
IV total scores in the primary analysis.
Analyses of the ADHD-RS-IV subscale scores and the Conners
Early Childhood Behavior—Parent Short Response score were
conducted the same way as for the ADHD-RS-IV total score.
Analysis of the change in CGI-S from the end of the open-label
phase to the end of the DB phase was using the Cochran–Mantel–
Haenszel chi-square test.
Our effect size (ES) calculation was based on a study that
demonstrated that a change of 10 to 15 points in ADHD-RS-IV total
scores corresponded to a change of one level in CGI-I rating
(Goodman et al. 2010), and on calculating the difference between
treatment groups in change from baseline during Phase 5. The ES
calculation was supported by the additional calculation of dividing




Of the 194 children screened, 132 entered the enrollment and
parent training phase, 128 entered the eligibility for open-label
treatment phase, 119 entered open-label treatment, and 90 were
randomized to DB treatment (40 to MPH-MLR, 50 to placebo;
Fig. 2). Twenty children bypassed the BMT. Baseline demographics
of enrolled children are given in Table 1. In the safety population
(N = 119), the most common ADHD diagnosis subtype was com-
bined with 88.0% and 89.9% reported for the placebo and MPH-
MLR treatment groups, respectively. The percentages of children
with hyperactive/impulsive subtype were 12.0% and 8.4% in the
placebo and MPH-MLR treatment groups, respectively. A small
percentage of children (1.7%) in the MPH-MLR treatment group
were diagnosed with the inattentive subtype. Mean (SD) ADHD-RS-
IV total scores at open-label start and open-label end were 40.8
(10.4) and 19.5 (11.1), respectively. The median optimized dose
during the open-label phase was 30 mg (mean, 27.5 mg).
Primary endpoint
Mean (SD) ADHD-RS-IV total scores at the beginning of the DB
period (Visit 13) were similar in children randomized to MPH-
MLR (19.5 [11.1]) and placebo (17.8 [9.9]; p = 0.309). Mean (SD)
ADHD-RS-IV total scores for the MPH-MLR and placebo group
were 25.8 (14.6) and 34.9 (14.1), respectively, at DB end.
For the ITT-E population, the mean change from baseline in
ADHD-RS-IV total score during the DB Phase 5 was significantly
greater in children randomized to placebo compared with MPH-
MLR. The difference in the least squares mean change from baseline
(MPH-MLR group least squares mean change from baseline minus
placebo group least squares mean change from baseline) was -11.2
(95% confidence interval [CI] = -18.0 to -4.4; p = 0.002; Fig. 3a),
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meaning that the loss of pre-established treatment effect after open-
label treatment with MPH-MLR was significantly greater in children
randomized to placebo than those randomized to continue on MPH-
MLR. The ES was -1.1, slightly more than a minimally clinically
significant difference in ADHD-RS-IV total score in favor of the
MPH-MLR group. When this analysis was repeated in the DBC-15
population, the difference in least squares mean change from base-
line in ADHD-RS-IV total scores during Phase 5 was also signifi-
cantly greater in children randomized to placebo compared with
MPH-MLR (Fig. 3b).
Table 1. Baseline Demographics and Characteristics
Parameter
ITT population Enrolled population
MPH-MLR (n = 40) Placebo (n = 50) Overall (N = 90) Overall (N = 158)
Age, months
Mean (SD) 58.5 (5.6) 59.2 (6.4) 58.9 (6.1) 58.8 (6.2)
Median (Q1, Q2) 57.0 (55.0, 63.5) 59.0 (54.0, 64.0) 59.0 (55.0, 64.0) 58.5 (53.0, 64.0)
Minimum, maximum 49, 69 48, 70 48, 70 48, 70
Sex, n (%)
Male 29 (72.5) 39 (78.0) 68 (75.6) 121 (76.6)
Female 11 (27.5) 11 (22.0) 22 (24.4) 37 (23.4)
Race, n (%)
White 24 (60.0) 30 (60.0) 54 (60.0) 82 (51.9)
Black or African American 15 (37.5) 18 (36.0) 33 (36.7) 70 (44.3)
Asian 0 1 (2.0) 1 (1.1) 1 (0.6)
Other 1 (2.5) 1 (2.0) 2 (2.2) 4 (2.5)
Hispanic or Latino 5 (12.5) 6 (12.0) 11 (12.2) 17 (10.8)
Characteristic
Mean (SD) height, cm 110.4 (4.9) 110.8 (5.8) 110.6 (5.4) 110.9 (5.4)a
Mean (SD) weight, kg 20.2 (3.1) 20.5 (3.8) 20.3 (3.4) 20.4 (3.4)a
Mean (SD) body mass index, kg/m2 16.5 (1.7) 16.6 (2.4) 16.6 (2.2) 16.5 (2.0)a
an = 157.
ITT, intention-to-treat; MPH-MLR, methylphenidate hydrochloride extended-release capsules.
Enrolled 
N = 158  
Bypassed parent training;
waiver granted or patient























(No Visit 15 ADHD-RS-IV score: n = 1;
with Visit 15 ADHD-RS-IV score: n = 2)Included in primary
endpoint analysis
n = 88 
Discontinued
n = 2




FIG. 2. Disposition. ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale Fourth Edition; ITT-E, intention-to-treat—
efficacy evaluable.
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Secondary efficacy endpoints
In the ITT-E population, mean change from baseline in ADHD-
RS-IV hyperactivity/impulsivity and inattention scores during the
DB Phase 5 were significantly greater in children randomized to
placebo compared with MPH-MLR; the difference in the least
squares mean change from baseline (MPH-MLR group least squares
mean change from baseline minus placebo group least squares mean
change from baseline) was hyperactivity/impulsivity -6.2 (95%
CI = -9.8 to -2.6; p = 0.001) and inattention -5.0 (95% CI = -8.4 to
-1.6; p = 0.005).
CGI-S was evaluated at Visit 13, baseline for the DB Phase 5,
and again at the end of Phase 5 (Visit 15; Table 2). Analysis of
each treatment group at the end, relative to the beginning of Phase
5, indicated that children in both treatment groups had signifi-
cantly higher severity ratings at Visit 15; the higher severity rating
in the MPH-MLR group is likely an artifact of the study design,
which permitted children to opt out of the DB phase before
completing 2 weeks of treatment and enter open-label treatment if
they had significant worsening of ADHD symptoms. In the DBC-
15 population, between-group analysis indicated no significant
difference between treatment groups at Visit 13; at Visit 15, the
MPH-MLR group had significantly lower CGI-S rating than pla-
cebo. At Visit 15, the placebo group had a significantly higher
CGI-S rating than at Visit 13.
Between-group analysis of the MPH-MLR and placebo groups
at Visit 15 indicated that the CGI-I rating was significantly worse in
the placebo group relative to the MPH-MLR group in the ITT-E
population (Table 3). This difference in CGI-I rating was not
mirrored in the DBC-15 populations, which may be related to the
reduced sample size relative to the ITT-E population. Analysis
of Conners Early Childhood Behavior—Parent Short Response
T-Scores from baseline to Visit 15 did not show any significant
differences between MPH-MLR and placebo in either the ITT-E or
DBC-15 populations (data not shown).
Safety
The profile of AEs was typical of that previously reported in
children with ADHD treated with MPH. During the 6-week, open-
label Phase 4, 95 (79.8%) children had at least one treatment-
emergent adverse event (TEAE), most of which related to study
treatment, which were mild or moderate in severity. The most
common TEAEs considered to be either possibly or probably
related to treatment were decreased appetite (18.5%), insomnia
(15.1%), decreased weight (14.2%), and irritability (13.4%), all of
which were considered by the investigator to be mild or moderate
in severity except for one instance of severe insomnia. One child
experienced a serious AE of Campylobacter infection during the
open-label phase that was considered unrelated to study treat-
ment. No deaths were reported during open-label treatment. No




FIG. 3. Primary endpoint: change in ADHD-RS-IV total score from baseline (Visit 13) to Visit 15 (end of double-blind Phase 5) in (a)
the ITT-E population and (b) the DBC-15 population. The smaller change in the MPH-MLR group suggests that symptom control was
better maintained in the MPH-MLR group versus the placebo group. ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating
Scale, Fourth Edition; CI, confidence interval; DBC-15, children in the double-blind compliant population who had 15 – 3 days of
participation in the double-blind phase of the study; ITT-E, intention-to-treat—efficacy evaluable; LS, least squares; MPH-MLR,
methylphenidate hydrochloride extended-release capsules.
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During the 2-week, DB Phase 5, TEAEs were experienced by 10
(25.6%) children treated with MPH-MLR and 6 (12.0%) children
treated with placebo (Table 4). The most commonly reported AEs
considered to be either possibly or probably related to MPH-MLR
were hypertension (7.7%), and emotional poverty, negativism,
pollakiuria, onychophagia, decreased appetite, and tachycardia
(2.6% each). All the TEAEs in the DB phase were deemed to be
either mild or moderate in severity, except for a TEAE of severe
negativism in one subject. No subjects experienced a serious AE
during the DB phase and no deaths occurred.
The withdrawal of 13 subjects was attributed to TEAEs; 12
subjects withdrew from Phase 4 and one from Phase 5. At the time
of withdrawal, five subjects were receiving MPH-MLR 15 mg, five
subjects 20 mg, and three subjects 30 mg. One child had an emo-
tional disorder (severe emotional dysregulation), which was con-
sidered severe and possibly treatment related by the investigator.
The remaining TEAEs leading to withdrawal were considered mild
or moderate in severity.
The CSHQ was used to assess the effect of MPH-MLR on sleep
quality. During the 2-week, DB phase, the mean CSHQ total score
Table 3. Summary of Clinical Global Impression-Improvement Ratings at Beginning
and End of the Double-Blind Phase 5
Number (%) with the rating
ITT-E DBC-15
MPH-MLR (n = 39) Placebo (n = 50) MPH-MLR (n = 28) Placebo (n = 26)
CGI-I (Visit 15)
1 = Very much improved 6 (15.4) 5 (10.0) 5 (17.9) 3 (11.5)
2 = Much improved 8 (20.5) 6 (12.0) 8 (28.6) 6 (23.1)
3 = Minimally improved 3 (7.7) 4 (8.0) 3 (10.7) 2 (7.7)
4 = No change 11 (28.2) 13 (26.0) 10 (35.7) 10 (38.5)
5 = Minimally worse 4 (10.3) 1 (2.0) 2 (7.1) 1 (3.8)
6 = Much worse 6 (15.4) 16 (32.0) 0 4 (15.4)
7 = Very much worse 1 (2.6) 5 (10.0) 0 0
Between-group Cochran–Mantel–Haenszel
statistic: row mean scores difference p-valuea
0.045a 0.128b
aCochran–Mantel–Haenszel p-value for the comparison of the MPH-MLR treatment group to the placebo group distribution of CGI-S ratings across
the seven possible responses at the given time point.
bCochran–Mantel–Haenszel p-value for the comparison of the MPH-MLR treatment group to the placebo group distribution of CGI-I ratings across
the 7 possible responses at the given time point.
CGI-I, Clinical Global Impression—Improvement scale; DBC-15, children in the double-blind compliant population who had 15 – 3 days of
participation in the double-blind phase of the study; ITT-E, intention-to-treat—efficacy evaluable; MPH-MLR, methylphenidate hydrochloride extended-
release capsules.
Table 2. Summary of Clinical Global Impression—Severity Ratings at Beginning
and End of the Double-Blind Phase 5
Number (%) with the rating
ITT-E DBC-15
MPH-MLR (n = 39) Placebo (n = 50) MPH-MLR (n = 28) Placebo (n = 26)
CGI-S (Visit 13)
1 = Normal, not at all ill 7 (17.9) 13 (26.0) 5 (17.9) 3 (11.5)
2 = Borderline mentally ill 15 (38.5) 14 (28.0) 10 (35.7) 6 (23.1)
3 = Mildly ill 8 (20.5) 11 (22.0) 6 (21.4) 6 (23.1)
4 = Moderately ill 7 (17.9) 11 (22.0) 6 (21.4) 10 (38.5)
5 = Markedly ill 1 (2.6) 1 (2.0) 1 (3.6) 1 (3.8)
6 = Severely ill 1 (2.6) 0 0 0
7 = Among the most extremely ill subjects 0 0 0 0
CGI-S (Visit 15)
1 = Normal, not at all ill 4 (10.3) 3 (6.0) 4 (14.3) 2 (7.7)
2 = Borderline mentally ill 12 (30.8) 5 (10.0) 11 (39.3) 4 (15.4)
3 = Mildly ill 5 (12.8) 4 (8.0) 5 (17.9) 4 (15.4)
4 = Moderately ill 6 (15.4) 10 (20.0) 5 (17.9) 6 (23.1)
5 = Markedly ill 10 (25.6) 19 (38.0) 2 (7.1) 8 (30.8)
6 = Severely ill 2 (5.1) 7 (14.0) 1 (3.6) 2 (7.7)
7 = Among the most extremely ill subjects 0 2 (4.0) 0 0
Within-group Cochran–Mantel–Haenszel statistic:
row mean scores difference p-valuea
0.021 <0.0001 0.586 0.039
aCochran–Mantel–Haenszel p-value for the comparison within the indicated treatment group of Visit 15 to Visit 13 distribution of CGI-S ratings across
the seven possible responses.
CGI-S, Clinical Global Impression—Severity scale; DBC-15, children in the double-blind compliant population who had 15 – 3 days of participation in
the double-blind phase of the study; ITT-E, intention-to-treat—efficacy evaluable; MPH-MLR, methylphenidate hydrochloride extended-release
capsules.
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increased by 0.2 for placebo and did not change for the MPH-MLR
group, with no significant differences between the treatment groups
( p = 0.858). The changes in subscale scores during the DB phase
were minimal for both treatment groups, and no significant dif-
ferences between groups were found.
Discussion
In this first randomized, placebo-controlled trial of an ER MPH
formulation in preschool children aged 4 to <6 years, MPH-MLR
dosages up to 40 mg were efficacious and well tolerated. During the
open-label, dose-optimization phase, children whose MPH-MLR
dose was optimized exhibited, on average, a 21.3-point reduction in
their ADHD-RS-IV total score versus baseline, consistent with a
robust improvement in ADHD symptoms (ES -1.1 for the DB
Phase 5 and -2.7 for the dose-optimized, open-label Phase 4). This
reduction in ADHD-RS-IV total score was maintained during the
DB phase in children randomized to MPH-MLR but not placebo.
ADHD-RS-IV total scores at baseline were not significantly dif-
ferent between treatment groups, indicating that the mean change in
ADHD-RS-IV total score difference was not likely related to
baseline severity. The safety profile of MPH-MLR in this study was
consistent with what is already known about MPH use for ADHD,
and it extends this information to the preschool population.
It is interesting to contrast the current findings with those in the
National Institute of Mental Health-funded PATS. In PATS,
165 preschool children were treated with IR MPH in doses up to
22.5 mg, achieving a mean optimal dose of 14.2 – 8.1 mg/day
(0.7 – 0.4 mg/kg/day) (Greenhill et al. 2006). Seven (4%) pre-
schoolers were classified as nonresponders and 14 (8%) were
classified as placebo responders. The ESs for MPH were 0.2–0.7
during the titration phase and 0.2–0.9 during the parallel phase.
These ESs were smaller than those seen in school-aged children
treated with MPH in the Multimodal Treatment Study of ADHD
(Greenhill et al. 2001), and smaller than those observed in our study.
In PATS, AEs that were statistically more frequent on MPH than
placebo included decreased appetite, insomnia, and weight loss
during dose titration (Wigal et al. 2006). During the open-label
phase of our study, we had a similar AE profile, which, with the
exception of one report of severe insomnia, included AEs of mild or
moderate severity. Of interest, in this study, the mean optimized
dose was almost twice the mean optimal dose achieved during
Table 4. Summary of the Most Common Treatment-Emergent Adverse Events (Incidence ‡2%) Encountered During
the 2-Week Double-Blind Phase 5 (Safety Population)
System organ class preferred term
MPH-MLR (n = 39) Placebo (n = 50)
n (%) No. of events n (%) No. of events
Any TEAE 10 (25.6) 14 6 (12.0) 9
Psychiatric disorders
Emotional disorder 0 0 1 (2.0) 1
Onychophagia 1 (2.6) 1 0 0
Emotional poverty 1 (2.6) 1 0 0
Negativism 1 (2.6) 1 0 0
Infections and infestations
Upper respiratory tract infection 2 (5.1) 2 0 0
Cellulitis 0 0 1 (2.0) 1
Sinusitis 0 0 1 (2.0) 1
Metabolism and nutrition disorders
Decreased appetite 1 (2.6) 1 0 0
Gastrointestinal disorders
Vomiting 0 0 1 (2.0) 1
Gastritis 1 (2.6) 1 0 0
Vascular disorders
Hypertension 3 (7.7) 3 0 0
General disorders and administration site conditions
Pyrexia 0 0 1 (2.0) 1
Adverse event 1 (2.6) 1 0 0
Musculoskeletal and connective tissue disorders
Pain in extremity 0 0 1 (2.0) 2
Renal and urinary disorders
Pollakiuria 1 (2.6) 1 0 0
Urinary incontinence 1 (2.6) 1 0 0
Injury, poisoning, and procedural complications
Injury corneal 0 0 1 (2.0) 1
Skin and subcutaneous tissue disorders
Rash 0 0 1 (2.0) 1
Cardiac disorders
Tachycardia 1 (2.6) 1 0 0
MPH-MLR, methylphenidate hydrochloride extended-release capsules; TEAE, treatment-emergent adverse event.
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PATS (Greenhill et al. 2006). The IR component of MPH-MLR
comprises *40% of the total dose (Aptensio XR [methylpheni-
date extended release] 2017). In the PATS the 14 mg averaged
optimized dose was divided into three daily doses. Thus, the initial
IR MPH-MLR dose of 12 mg in this trial was *2.5 times the
average PATS morning dose (Greenhill et al. 2006). Preschool
children in our study tolerated the higher doses with a robust re-
sponse comparable with what is seen when older children are ad-
ministered MPH-MLR (Wigal et al. 2015). The ER component of
MPH-MLR may have improved tolerability throughout the day.
We observed a relative increase in ADHD-RS-IV total score
change from baseline in children randomized to MPH-MLR in the
DB phase, not only those randomized to placebo. This slight
worsening of symptoms is consistent with the negative effects of
expectancy when children are transitioned from optimized active
medication to randomized treatment with either active medication
or placebo (Coghill et al. 2014).
In our study, preschool children had to fail BMT, considered the
first-line treatment in the United States (Wolraich et al. 2011),
before moving on to active dosing during the optimization phase.
This suggests that children treated with MPH-MLR had impair-
ments not adequately addressed with BMT.
In this study, MPH-MLR exerted minimal negative effects on
sleep quality compared with placebo. It is possible that this finding
is related to the fact that children with sleep problems either do not
enroll in these studies or discontinued during the open-label titra-
tion phase. In two studies in older children and adolescents, opti-
mizing the dose of MPH-MLR actually improved most CSHQ
(or the adolescent version) measures (Owens et al. 2016).
Study limitations
This study was relatively brief, and sustained effects of treat-
ment on longer term ADHD functioning cannot be inferred; this is
an important direction for future research, given the chronic nature
of ADHD. No standardized scale for assessment of TEAEs was
used; rather, the presence of TEAEs was spontaneously reported.
Although solicited reports of AEs have been shown to result in
higher reporting rates, they have not led to improved detection of
differences between treatment and placebo (Wernicke et al. 2005).
In addition, although the CGI was used to assess global im-
provement, and found to be different between the drug and pla-
cebo groups, the primary focus on assessment of symptoms
(ADHD-RS-IV), rather than other aspects of functioning, may
have obscured other facets of functional impairment and their
relationship to treatment. Of note, the relationship between
symptom reduction and global improvement has been shown to be
somewhat divergent in other clinical trials (Coghill et al. 2017;
Kollins 2018; Weiss et al. 2018). Further investigation of the
functional aspects of treatment response in the preschool popu-
lation is therefore required.
Conclusions
MPH-MLR at doses up to 40 mg was efficacious and well tol-
erated in preschool children 4 to <6 years of age with ADHD. The
safety profile of MPH-MLR in preschool children was consistent
with the known safety profile of MPH in older children. These data
are the first from a randomized, placebo-controlled trial to support
the use of an ER MPH formulation, MPH-MLR, as an option for the
clinical management of ADHD in preschool children when be-
havior therapy has not been successful.
Clinical Significance
These findings provide empirical data to support the use of
MPH-MLR in young children with a verified diagnosis of ADHD.
Of importance, to mirror recommended treatment guidelines for the
preschool population, children in the trial participated in non-
pharmacological treatment before enrolling (or were otherwise
deemed eligible to initiate pharmacotherapy), and showed robust
benefit from treatment, as measured by improvements in ADHD
symptoms.
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